Navigation Links
Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
Date:8/27/2009

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

"Based on the results of our extensive clinical research studies and our European commercial experience, we believe that our PROGENSA PCA3 assay can help predict the risk of a positive follow-up biopsy, thereby improving patient care," said Eric Lai, PhD, Gen-Probe's senior vice president of research and development. "In addition, this is an important step forward in our efforts to maximize the economic value of our oncology strategy."

The clinical study of the PROGENSA PCA3 assay is expected to conclude in less than a year, after which Gen-Probe intends to submit a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration. The Company anticipates the trial will enroll approximately 500 men, all of whom have had a negative prostate biopsy, at 10 or more clinical trial sites.

Data from more than 20 peer-reviewed publications suggest that the PROGENSA PCA3 assay, when used in conjunction with other patient information, may help address some of the well-known challenges urologists face when identifying prostate cancer, such as minimizing unnecessary biopsies.

According to the American Cancer Society (ACS), prostate cancer is the second most common type of cancer found in American men (behind skin cancer), and the second-leading cause of cancer death in men (after lung cancer). One in six American men will get prostate cancer during his lifetime, and one in 35 will die from it. The ACS estimates that more than 19
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
4. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
5. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
6. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
7. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
8. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
9. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
10. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
11. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
(Date:8/19/2014)... , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today ... Annual Meeting of the American Academy of ... Care Surgery in Philadelphia, Pennsylvania ... The presentation will report results from a recently ...
Breaking Medicine Technology:AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... NEW YORK, Oct. 31 A recent outbreak ... to,as "the superbug," should cause organizations and facilities ... The superbug is resistant to common antibiotics. ... abscesses, boils and other pus-filled,lesions. Superbug infections prior ...
... Oct. 31 United,Therapeutics Corporation (Nasdaq: UTHR ... today that they will release the results of ... formulation of treprostinil,in pulmonary arterial hypertension (PAH) before ... Therapeutics will expand its previously scheduled conference,call on ...
Cached Medicine Technology:'Superbug' Outbreak Calls for Immediate Increased Attention on Infection Control 2Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
(Date:8/20/2014)... IQ Formulations , a top national health ... Inc. 500 , distinguishing it as one of the fastest ... only made the list, but was ranked in the top ... three years. It also ranked ninth among all health companies, ... second fastest growing company in the Miami metro area. ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... Awards. PM360, a leading health-marketing industry trade magazine, will ... 2009, the Trailblazer Awards are given to outstanding companies, ... has to offer. , “We are proud to ... our call to entries with double the number of ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... world’s largest nutrition school, is proud to announce ... Integral Studies (CIIS), a cutting-edge university offering ... Nutrition’s Health Coach Training Program are now eligible ... of Arts in Integrative Health Studies. , “I’m ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3
... cohort studies on the association of alcohol consumption with colorectal ... 2 from Australia, 13 from Western Europe, and 24 from ... least at higher levels of consumption, is associated with an ... was no increase in the risk for consumers reporting an ...
... , TUESDAY, Sept. 13 (HealthDay News) --The lifestyle changes ... disease may also improve sexual function in men with ... from the Mayo Clinic in Rochester, Minn., analyzed six ... determine how lifestyle changes and drugs used to treat ...
... for an effective vaccine and treatment against the potentially fatal ... the discovery of two ,Achilles, heels, within the virus. ... South Wales (UNSW) studied individuals at high risk of HCV ... the onset of infection. Using a new technique ...
... Canadian researchers has found the first evidence that lifelong ... While hearing studies have already shown that trained musicians ... is the first study to examine hearing abilities in ... 18 to 91 years of age. The study ...
... HealthDay Reporter , MONDAY, Sept. 12 (HealthDay News) -- ... become fathers, perhaps because they don,t need to compete with ... with their children. The findings don,t prove that fatherhood ... hormonal systems in men may detect that they,ve become fathers ...
... MONDAY, Sept. 12 (HealthDay News) -- Implantable electronic devices ... heart conditions and save lives, but these benefits may ... complications, a new study suggests. Researchers from the ... that people who develop an infection related to a ...
Cached Medicine News:Health News:Relation of alcohol consumption to colorectal cancer 2Health News:Breakthrough opens new avenues for hep C vaccine 2Health News:Science finding is music to the ears 2Health News:Testosterone Levels Seem to Fall With Fatherhood 2Health News:Testosterone Levels Seem to Fall With Fatherhood 3Health News:Heart Devices Like Pacemakers Linked to Infections 2
Inquire...
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
Medicine Products: